CagriSema has reached a stage where its clinical results deserve a closer look than a headline percentage. The combination pairs cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. Its Phase 3 studies show substantial average weight reductions, while the statistical analysis, population and regulatory status determine what those results actually mean.
Approval status: development milestones are separate decisions
Novo Nordisk announced a US application on 18 December 2025 for its investigational once-weekly injectable combination. That establishes a submission, not approval. The 30 September 2026 sponsor update continues to describe development of the investigational product. The current FDA safety communication says cagrilintide is not a component of an FDA-approved drug. No EU marketing authorisation was verified in this review.
Keep the labels “Phase 3 evidence”, “submitted for approval” and “approved product” separate. Availability, reimbursement and an eventual prescribing label require additional information. The CagriSema regulatory watch follows dated developments, while the drug tracker profile provides the entity overview. Neither should be read as a route to buy an investigational drug.
Two pivotal trials, two different populations
REDEFINE 1 and REDEFINE 2 both ran for 68 weeks with lifestyle intervention. Their similarities make them useful to examine together; their different eligibility rules prevent the results from becoming one universal expected weight loss.
| Trial and population | Randomised participants | Treatment-policy result | Trial-product estimate |
|---|---|---|---|
| REDEFINE 1: adults with obesity, or overweight plus a complication; no diabetes | 3,417 across combination, semaglutide, cagrilintide and placebo arms | Combination −20.4%; placebo −3.0% | Combination −22.7%; placebo −2.3% |
| REDEFINE 2: adults with type 2 diabetes, BMI at least 27 and HbA1c 7–10% | 1,206 across combination and placebo arms | Combination −13.7%; placebo −3.4% | Combination −15.7%; placebo −3.1% |
Trial doses were cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly. They identify the experimental regimen and are not instructions for self-treatment. Participant counts above come from the papers; a registry may list a different enrollment count or an earlier estimate. An article should not silently substitute one denominator for the other.
Why 20.4% and 22.7% can both describe REDEFINE 1
The treatment-policy estimand asks about the treatment strategy even when participants stop the trial medication or use other weight-loss treatments. The trial-product estimand estimates a scenario in which participants remain on the assigned product without those other treatments. Missing-data assumptions and the statistical model also matter; the latter is not simply a raw average of successful completers.
That distinction changes the question rather than making one figure “real” and the other “fake”. The continued-treatment estimate can illuminate pharmacological efficacy under its assumptions. The treatment-policy estimate is useful for considering a strategy that includes the possibility of interruption. Neither is a guarantee of an individual response.
Our editorial approach is to put the analysis label beside every main number. When comparing a sponsor headline with a paper, check the estimand before looking for a contradiction. The same discipline is needed in comparisons with other medicines: a higher estimate from one trial cannot defeat a lower estimate from another if they describe different populations or different assumptions. See how to read weight-loss trials for a worked reading framework.
The value of having an active comparator
REDEFINE 1 included semaglutide and cagrilintide arms as well as placebo. Under the treatment-policy analysis, mean changes were −14.9% with semaglutide and −11.5% with cagrilintide; the combination’s estimated difference versus semaglutide was −5.5 percentage points. This is a comparison inside the same randomised study, which is more informative than placing unrelated trial averages beside each other.
Its scope still matters. It compares the specified doses and the enrolled population over the study period. It does not answer every question about the highest currently approved semaglutide dose, another drug, long-term organ outcomes or someone who would not have met enrollment criteria. It also does not make two separately purchased products equivalent to the studied combination.
The complementary-pathway rationale is worth studying, but a mechanism diagram is not an outcome trial. Our weight-loss medication mechanisms guide explains the broader landscape, including why receptor count alone is not a measure of clinical value.
Tolerability belongs beside the efficacy result
In REDEFINE 1, gastrointestinal adverse events were reported in 79.6% of the combination group and 39.9% of the placebo group. REDEFINE 2 reported 72.5% and 34.4%, respectively. The papers describe most of these events as transient and mild to moderate. These percentages cover reported gastrointestinal events, not the percentage hospitalised, and they should not be relabelled as serious-event rates.
A statement that events were usually mild does not mean every participant tolerated treatment well. Safety assessment also includes discontinuation, serious events, laboratory findings and the length of follow-up. Different study designs and populations can affect reported rates. These two trials help establish the benefit-risk evidence under study conditions; they do not settle every rare risk or every consequence of years of use.
There is no approved CagriSema label verified here to use as a personal safety checklist. The safety information for semaglutide alone does not become a complete label for a new combination. FDA’s warning about cagrilintide compounding is also a reason to avoid confusing online “research” products with an approved prescription.
What remains unanswered
- Regulatory outcome: a dated regulator decision and final product information, with jurisdiction and indication specified.
- Long-term outcomes: weight loss alone cannot establish fewer heart attacks, less kidney failure or better survival.
- Routine-care persistence: how access, tolerability and sustained use affect outcomes outside the supported trial setting.
- Maintenance: what happens after interruption and how a long-term care strategy would work.
- Access: an eventual price, reimbursement policy and supply cannot be inferred from the trial’s efficacy.
REDEFINE 3 is a Phase 3 cardiovascular outcomes study, active but not recruiting at this review. Its endpoint concerns cardiovascular death, nonfatal heart attack or nonfatal stroke. An ongoing registry record explains what researchers plan to test; it does not show that the outcome has already improved.
A practical way to follow the next update
Start with the source type. A regulator notice changes approval status; an original paper changes the clinical evidence; a registry update changes what is known about study plans or progress. A sponsor release can announce a result or filing, but should remain clearly attributed. Then identify the population, intervention, comparator, duration and statistical question before revising an opinion.
This approach allows new information to strengthen the profile without replacing uncertainty with a predicted launch date. CagriSema is a serious development program with published evidence, and its next milestones deserve precise reporting. This article is educational and does not advise combining medicines, obtaining investigational products or choosing a personal dose.



